(Jakarta, May 11, 2025)
Daewoong Pharmaceutical has introducedits flagship botulinum toxin product, Nabota, along with its medical aesthetic portfolio to healthcare professionals in Indonesia.
Daewoong Pharmaceutical (Co-CEOs SeongsooPark and Chang-jae Lee), in partnership with CnG Bio Indonesia(CBI), participated in the ‘2025 WeSWAM’ conference held at El Royale Hotel in Bandung, Indonesia,from April 25 to 27, 2025.
The 2025 WeSWAM, one of the regional events in the series of Indonesia’s largest aesthetic medicine conference SWAM,was held in West Java near Jakarta.
Organized by the Indonesian Society ofAesthetic Medicine (PERDESTI), SWAM (Seminar & Workshop in Aesthetic Medicine) is the largest international aesthetic medicine conference inIndonesia, held five times a year across major cities and attracting over 2,000medical professionals annually.
The 2025 WeSWAM focused on practical training, peer networking, and the exchange of clinical experiences. Thisyear’s event gathered approximately 300 medical professionals, 14 speakers, and31 sponsors to share insights on the latest trends and hands-on techniques in aesthetic medicine.
At its dedicated exhibition booth, Daewoong announced the official launch of Nabota in Indonesia and showcasedCBI’s medical aesthetic portfolio, including the HA filler brand ‘DCLASSY’, absorbable thread ‘DOOTH’, PDO (Polydioxanone) thread ‘LUXX’,and the calcium hydroxyapatite (CaHA)-based skin booster ‘Facetem’.
In particular, Daewoong activelypromoted its global expert training program, DEEP (Daewoong Medical-AEstheticExpert Program). DEEP is a global education initiative that brings together Daewoong’s extensive expertise in medical aesthetics. It invites aestheticmedicine professionals to participate in in-depth lectures and hands-ontraining sessions that can be immediately applied in clinical practice, alongwith academic exchanges that facilitate the sharing of insights among medical professionals.
Nabota is a premiumbotulinum toxin produced using Daewoong’s HI-PURE™ Technology, patented in Korea and the U.S., and a vacuum-drying process, resulting in a high-purity product (over 98% of 900kDa toxin) with rapid onset of action and minimized risk of inactive toxin formation, which can cause resistance.
Nabota has received regulatory approvals in 69 countries, including theU.S. FDA, EMA, Health Canada, and Indonesia’s BPOM, and has formed partnershipsin over 80 countries—solidifying its rapidly growing global presence.
Jun-Soo Yun, Head of Daewoong’s Nabota Business Division, stated, “Through these activities, Daewoong Pharmaceutical aims to establish itself as a leading brand for combination aesthetic procedures in Asia. Our long-term goal is to become Asia’s No.1 integrated aesthetic solution provider—delivering innovative solutions and patient safetythrough science-backed products and professional education.”
Chang-woo Ha, the Head of Aesthetic Business for Daewoong Group in Korea and Indonesia, added, “We have officiallylaunched our customized combination treatment portfolio and the DEEP experttraining program with Daewoong Pharmaceutical. Through the DEEP program, wewill share our expertise based on a diverse portfolio and aim to lead a healthyand in-depth medical aesthetics market.”
Starting with WeSWAM, Daewoong Pharmaceutical plans to continue its comprehensive DEEP education roadmap with webinars in May, AMUSE workshops and lectures in June, and a formal product launch symposium in July. The company aims to provide advanced aesthetictreatments to Indonesian medical professionals and, under the vision “Move toNEW GEN” strengthen both brand awareness and expertise as a next-generationleader in the local aesthetics industry.
# # #
[Photo]
▲ Medical professionals are visiting the Nabota booth at WeSWAM, Indonesia’s largest aesthetic medicine conference, held in Bandung, Indonesia.